

a 3 least one product [lymphoid gene products] and predicted to be high when a high percentage of the tumor cells in at least one of the samples are detected to express said at least one product [lymphoid gene products].

Cancel claims 2 to 5, pursuant to the restriction requirement and without prejudice to the right of Applicant to file a divisional application thereto.

REMARKS

Withdrawn claims 2 to 5 have been canceled pursuant to the restriction requirement and without prejudice to the right of Applicant to file a divisional application thereto.

Applicant has withdrawn the claim of priority.

As required by the Examiner, the specification has been amended to describe Figs. 22A and 22B separately. The other objection by the Examiner to the specification has been rendered moot by the withdrawal of priority. The specification has also been amended to correct what are clearly clerical errors, including more clearly aligning the columns with the headings in table 3 (page 20).

Claim 1 has been rejected under 35 USC 112, second paragraph, on the basis that "lymphoid gene products" is vague and indefinite. Claim 1 has been amended to more clearly define what Applicant regards as the invention. As amended, claim 1 does not contain the phrase "lymphoid gene products". It is respectfully submitted that, as amended, claim 1 particularly points out and distinctly claims the subject matter which Applicant regards as the invention. It is therefore respectfully requested that the rejection of claim 1 under 35 USC 112, second paragraph, be withdrawn.

RECEIVED
JAN 10 1994
TECH CENTER 1800 2000

Claim 1 has been rejected under the doctrine of obviousness-

X